Tengion to Host Conference Call to Provide a Business Update and Report Third Quarter 2011 Financial Results on November 14, 2011
EAST NORRITON, Pa., Nov. 7, 2011 /PRNewswire/ — Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, November 14, 2011 at 5:00 p.m. EST to provide a business update and discuss its third quarter 2011 financial results.
To participate in the call, please dial 1-800-299-0148 (domestic) or 1-617-801-9711 (international) and reference access code 45190334.
This conference call will also be webcast live and can be accessed from the Investors section of the Company’s website at http://www.tengion.com or at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=218965&eventID=4234367. The webcast will also be archived on the website.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform((TM)) that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion’s Neo-Bladder Augment for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.